Fenwick & West represented Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers, in its definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY). Under the terms of the agreement, Lilly will commence a tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash, or approximately $8.0 billion. The transaction is expected to close by the end of the first quarter of 2019, subject to customary closing conditions. More information about Loxo Oncology’s acquisition by Lilly can be obtained from the company announcement.
The Fenwick transaction team included corporate lawyers Effie Toshav, Doug Cogen, David Michaels, Stephen Fisher, Andrew Murphy and Michelle Zheng; securities lawyers Rob Freedman, Julia Forbess and Michelle Fang; technology transactions lawyers Stefano Quintini, Sophia Chen, Ed Heffernan, Gina Damiano, Jefferson Lin, Ari Fink, Amy Brown, Shitel Chanana, Shizuka Tiernan, Karen Hagen and Jungso Choi; executive compensation and employee benefits lawyers Scott Spector, Matt Cantor, Nicholas Frey, Laura McIntyre and Sarah Ghulamhussain; tax lawyers Will Skinner and David de Ruig; and antitrust lawyers Mark Ostrau and Ashley Walter.